Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

UBS's Michael Yee raised their price target on Anaptysbio (NASDAQ: ANAB) by 28.6% from $70 to $90 on 2026/03/17. The analyst maintained their Strong Buy rating on the stock.

Anaptysbio reported its Q4 and FY 2025 earnings.

According to Yee, the stock's valuation is made up of $35 to $40 from the company's royalty business and the biopharma segment is worth $45 to $50 per share.

Looking ahead, the analyst said Anaptysbio's pipeline, especially the CD122 antagonist ANB033 in celiac disease, has the potential to become a blockbuster and significantly boost the stock price.

Earnings Report

AnaptysBio reported:

For Q4 2025:

• EPS of $1.58, which beat the Zacks Consensus Estimate of $0.89 and Q4 2024's $(0.72).
• Revenue of $108.25M, which beat the Zacks Consensus Estimate by 28.47% and Q4 2024's $43.11M.

For FY 2025:

• EPS of $(0.46), up from FY 2024's $(5.12).
• Revenue of 234.6M, up from FY 2024's $91.3M.

Management did not provide financial guidance in its press release.

President & CEO Daniel Faga commented: “We are approaching a defining inflection point for Anaptys, as we plan to spin-off in Q2 2026 our wholly owned biopharma portfolio into a public company, to be called First Tracks Biotherapeutics, to unlock and amplify value for investors across two distinct sets of assets.

“In our royalty portfolio, Jemperli exited Q4 2025 on a ~$1.4 billion annualized run rate, reinforcing GSK’s peak sales guidance of far more than $2.7 billion2 in monotherapy indications.

"At the same time, our biopharma portfolio is advancing multiple attractive, high-potential assets, including ANB033, which has pipeline-in-a-product potential, initially in a Phase 1b trial for both celiac disease and eosinophilic esophagitis.”